GWM
WST icon

Gitterman Wealth Management’s West Pharmaceutical WST Stock Holding History

Gitterman Wealth Management’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-655
Closed -$143K – 337
2025
Q2 		$143K Buy
+655
New +$140K 0.03% 201
2021
Q3 		– Sell
-689
Closed -$247K – 89
2021
Q2 		$247K Buy
+689
New +$228K 0.2% 48

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return

Gitterman Wealth Management's WST Position: Q3 2025 in Review

Gitterman Wealth Management sold out of West Pharmaceutical (WST) in Q3 2025, closing a stake of 655 shares — an estimated $143K sold.

Gitterman Wealth Management first reported a position in WST in Q2 2021 and held it in 2 quarters. The position peaked at $247K in Q2 2021. 756 funds tracked by Wall St. Rank hold WST as of Q3 2025.

  • Gitterman Wealth Management reported no remaining West Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Gitterman Wealth Management sold 655 West Pharmaceutical shares in Q3 2025, an estimated $143K.
  • Gitterman Wealth Management first reported a position in West Pharmaceutical in Q2 2021 and held it in 2 quarters.
  • Gitterman Wealth Management's West Pharmaceutical position peaked at $247K in Q2 2021.
  • 756 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2025.

Based on Gitterman Wealth Management's 13F filing for Q3 2025, filed 4 Nov 2025.